<abstract xmlns="http://www.w3.org/1999/xhtml">

This study aimed to modify screen-printed carbon micro-electrode surfaces by coating them with multiwall carbon-based nanotubes conjugated with chitosan and then validated the formed multiwall carbon-based nanotubes-chitosan coated screen printed carbon micro-electrode for the detection of homocysteine, a biomarker analyte known as a risk indicator in cardiovascular disease. The microstructure surface and crystallographic structure stability of the formed multiwall carbon-based nanotubes-chitosan obtained at formed multiwall carbon-based nanotubes per chitosan ratios of 1:1, 2:1, 3:1, and 4:1 were examined via field emission scanning electron microscopy, X-ray radiation, Raman spectroscopy, surface area and pore size, and thermogravimetric analyses. Homocysteine solutions at 30–100 µM were measured by cyclic voltammetry using the different formed multiwall carbon-based nanotubes-chitosan compositions as sensor electrodes. That with an optimal formed multiwall carbon-based nanotubes per chitosan ratio of 4:1 showed the highest crystallinity and electrical conductivity and gave a high coefficient of determination (R2 = 0.9036) between the homocysteine concentration and the oxidation current detection over an operating range of 30–100 µM. This new composite microelectrode for detecting homocysteine concentration makes it a promising candidate for clinical applications.
</abstract>

Department of Materials and Textile Technology, Faculty of Science and Technology

The Avram and Stella Goldstein-Goren Department of Biotechnology Engineering

Electrode surfaces based on multiwall carbon nanotubes-chitosan composites validated in the detection of homocysteine biomarkers for cardiovascular disease risk monitoring

<abstract xmlns="http://www.w3.org/1999/xhtml">

The study has developed a model splicing construct assay system based on splicing misregulation, one of the major molecular features associated with myotonic dystrophy. The splicing construct assay has double reporters for intron 2 splicing in chloride channel (CLCN1). The CLCN1 transgene splicing construct assay was used to transfect wild type and DM fibroblast cell lines and the clones generated showed that it enabled quantification of splicing efficiency in transgene construct. Validation of the DM fibroblasts containing transgene splicing construct was performed by differentiating the DM fibroblasts into myoblasts which exhibited a switch in CLCN1 splicing construct which was consistent with that associated with myotonic dystrophy (DM) condition. The myoblast derived from fibroblasts cell-based gene-splicing assay was subsequently applied in therapeutic screening in small throughput screens of 113 compounds which identified Protein Kinase C inhibitors- hypericin and Ro-31-8220 as potential therapeutic agents. The CLCN1 gene-splicing assay is a good model system for application in therapeutic screening in myotonic dystrophy because its double reporters facilitated quantification of effect putative drug on correction of misregulated splicing.
</abstract>

Queen’s Medical Centre, University of Nottingham

A Cell-Based Double Reporter Gene Splicing Assay for Therapeutic Screening in Myotonic Dystrophy

AHEAD OF PRINT

Volume 8 (2024): Issue 2 (April 2024)

Volume 8 (2024): Issue 1 (January 2024)

Volume 7 (2023): Issue 4 (October 2023)

Volume 7 (2023): Issue 3 (July 2023)

Volume 7 (2023): Issue 2 (April 2023)

Volume 7 (2023): Issue 1 (January 2023)

Volume 7 (2023): Issue s1 (December 2023)

Volume 6 (2022): Issue 4 (October 2022)

Volume 6 (2022): Issue 3 (July 2022)

Volume 6 (2022): Issue 2 (April 2022)

Volume 6 (2022): Issue 1 (January 2022)

Volume 5 (2021): Issue 2 (April 2021)

Volume 5 (2021): Issue s2 (December 2021)

Volume 5 (2021): Issue s1 (June 2021)

Volume 5 (2021): Issue 4 (October 2021)

Volume 5 (2021): Issue 3 (July 2021)

Volume 5 (2021): Issue 1 (January 2021)

Volume 4 (2020): Issue 4 (October 2020)

Volume 4 (2020): Issue 3 (July 2020)

Volume 4 (2020): Issue 2 (April 2020)

Volume 4 (2020): Issue 1 (January 2020)

Volume 3 (2019): Issue 4 (October 2019)

Volume 3 (2019): Issue 3 (July 2019)

Volume 3 (2019): Issue 2 (April 2019)

Volume 3 (2019): Issue 1 (January 2019)

Volume 2 (2018): Issue 4 (October 2018)

Volume 2 (2018): Issue 1 (January 2018)

Volume 2 (2018): Issue s1 (September 2018)

Volume 2 (2018): Issue 3 (July 2018)

Volume 2 (2018): Issue 2 (April 2018)

Volume 1 (2017): Issue 4 (October 2017)

Volume 1 (2017): Issue 3 (July 2017)

Volume 1 (2017): Issue 1 (January 2017)

Volume 1 (2017): Issue s2 (December 2017) MAGI group activity - Research, diagnosis and treatment of genetic and rare diseases

Volume 1 (2017): Issue s1 (October 2017) EBTNA Utility Gene Test on Ophthalmology

Volume 1 (2017): Issue 2 (May 2017)

The EuroBiotech Journal

The EuroBiotech Journal is the official journal of the The European Biotechnology Thematic Network Association (EBTNA) and is published periodically every three months. It covers both the science of biotechnology. The journal publishes peer-reviewed research articles, reviews, brief reports, short communications and opinions in various areas of biotechnology. The EuroBiotech Journal presents the full diversity of biotechnology science, particularly advances in research and developments that open opportunities for exploitation of knowledge, commercially or otherwise, together with discussion and comment on broader issues of general interest and concern. The outlook is fully international.  The scope of the EuroBiotech Journal includes the research and industrial aspects of biotechnology, in areas including: Healthcare and Pharmaceuticals; Immunotherapy and Diagnostics; Genetic Engineering; Gene-Editing; Protein Engineering; Genomics; Synthetic Biology; Molecular technologies; Nanotechnology; Bioinformatics and Databases; and Digital technologies and Artificial Intelligence, where they relate to biotechnology.  The EuroBiotech Journal publishes only online, and all articles are available on our website free of charge. Each work will receive a unique DOI (Digital Object Identifier) number.  The EuroBiotech Journal is committed to publishing works in the field of biotechnology by researchers from all over the World which are innovative and contribute to scientific knowledge.  Archiving  Sciendo archives the contents of this journal in Portico - digital long-term preservation service of scholarly books, journals and collections.  Plagiarism Policy  The editorial board is participating in a growing community of Similarity Check System's users in order to ensure that the content published is original and trustworthy. Similarity Check is a medium that allows for comprehensive manuscripts screening, aimed to eliminate plagiarism and provide a high standard and quality peer-review process. 

The EuroBiotech Journal

Volume 7 (2023): Issue 3 (July 2023)

Electrode surfaces based on multiwall carbon nanotubes-chitosan composites validated in the detection of homocysteine biomarkers for cardiovascular disease risk monitoring

A Cell-Based Double Reporter Gene Splicing Assay for Therapeutic Screening in Myotonic Dystrophy

Wyszukiwanie

Wszystkie tomy i zeszyty w tym czasopiśmie